Megatrends happen in ophthalmology when new technology addresses existing patient needs and is met with physician acceptance. There’s no better example of this than the current landscape in glaucoma.
A prevalent and vision-threatening condition that was traditionally treated best with eye drops, glaucoma is now best approached by initial treatment with selective laser trabeculoplasty followed shortly by other interventional measures like drug delivery platforms. These include Durysta (bimatoprost intracameral implant) from AbbVie and iDose (travoprost intracameral implant) from Glaukos,